Recursion Pharmaceuticals (NASDAQ:RXRX) has aligned with the U.S. Food and Drug Administration on the primary endpoint for a planned Phase III study of its experimental treatment for familial ...
The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
If you picked Recursion Pharmaceuticals for its AI-first pitch and deep pharma ties, the past year has probably felt rough.